iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · IEX Real-Time Price · USD
10.36
+0.03 (0.24%)
Apr 19, 2024, 9:39 AM EDT - Market open
iTeos Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for iTeos Therapeutics stock have an average target of 33.25, with a low estimate of 27 and a high estimate of 44. The average target predicts an increase of 221.10% from the current stock price of 10.36.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2024.
Analyst Ratings
The average analyst rating for ITOS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $29 → $27 | Buy | Maintains | $29 → $27 | +160.74% | Mar 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +324.92% | Mar 7, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $32 → $29 | Buy | Maintains | $32 → $29 | +180.06% | Nov 13, 2023 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +218.69% | Oct 18, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $44 | Strong Buy | Maintains | $54 → $44 | +324.92% | Aug 9, 2023 |
Financial Forecast
Revenue This Year
23.05M
from 12.60M
Increased by 83.03%
Revenue Next Year
8.19M
from 23.05M
Decreased by -64.45%
EPS This Year
-4.85
from -3.15
EPS Next Year
-6.31
from -4.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 38.9M | 361.0M | 288.1M | 497.0M |
| Avg | 23.1M | 8.2M | 157.9M | 188.5M | 437.4M |
| Low | n/a | n/a | 25.2M | 109.2M | 362.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 733.7% | 68.5% | 4,305.5% | 82.5% | 163.7% |
| Avg | 83.0% | -64.5% | 1,826.7% | 19.4% | 132.0% |
| Low | - | - | 207.0% | -30.8% | 92.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.54 | -3.16 | 1.62 | 0.09 | 3.18 |
| Avg | -4.85 | -6.31 | -3.83 | 0.09 | 3.09 |
| Low | -5.80 | -8.18 | -7.62 | 0.09 | 2.97 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 3,365.7% |
| Avg | - | - | - | - | 3,266.7% |
| Low | - | - | - | - | 3,134.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.